BioPharmSignal logoBioPharmSignal

Biotech News

Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.

Repare Therapeutics (RPTX)Repare TherapeuticsCompany update

CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Jan. 16, 2026-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that its Shareholders (as defined below) have approved the acquisition of all of the issued and

Related news

GSKGSK plc2026-07-15 13:40 EST

GSK completes acquisition of Nuvalent, Inc.

ARGXArgenx2026-08-03 20:01 EST

argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026

TEVATeva Pharmaceutical Industries2026-06-10 16:03 EST

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy

View all latest news

Repare Therapeutics

Repare Therapeutics is an oncology company focused on precision medicine and synthetic lethality. Its story is built around targeting DNA damage-response vulnerabilities in cancer.

Recent company news

RPTXRepare Therapeutics2026-01-16 21:58 EST

Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.

RPTXRepare Therapeutics2025-12-24 12:00 EST

Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration

RPTXRepare Therapeutics2025-11-20 22:25 EST

Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.

RPTXRepare Therapeutics2025-11-14 21:44 EST

Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc.

RPTXRepare Therapeutics2025-10-13 20:05 EST

Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States